Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.

Journal of clinical psychopharmacology - 1 Apr 2016

Sukasem Chonlaphat, Hongkaew Yaowaluck, Ngamsamut Nattawat, Puangpetch Apichaya, Vanwong Natchaya, Chamnanphon Montri, Chamkrachchangpada Bhunnada, Sinrachatanant Ananya, Limsila Penkhae

Abstract excerpt

OBJECTIVE: The aim of the study was to identify the impact of pharmacogenetic markers associated with prolactin concentration in risperidone-treated children and adolescents with autism spectrum disorders. METHODS: One hundred forty-seven children and adolescents with autism, aged 3 to 19 years, received risperidone. The clinical data of patients were recorded from medical records. Prolactin levels were measured...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autism Spectrum Disorder
Share to Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Pharmacogenetics

Share to Prolactin

Share to Receptors, Dopamine D2

Share to Risperidone

Share to Thailand

Source

Identifiers

PMID: 26872113
DOI: 10.1097/JCP.0000000000000474

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.PMID 26872113Read ↗

The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.Semantic proximity Read ↗

Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder.Semantic proximity Read ↗

UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder.Semantic proximity Read ↗

Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implicationsSemantic proximity Read ↗

Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.Semantic proximity Read ↗

Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.Semantic proximity Read ↗

CYP2D6 polymorphisms and their influence on risperidone treatmentSemantic proximity Read ↗

The Frequency of CYP2D6 and CYP3A4/5 Genotypes and The Impact of Their Allele Translation and Phenoconversion-Predicted Enzyme Activity on Risperidone Pharmacokinetics in Saudi Children with Autism.Semantic proximity Read ↗

Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone.Semantic proximity Read ↗

Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects.Semantic proximity Read ↗

Pharmacogenetics of Clinical Response to RisperioneSemantic proximity Read ↗

The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.